Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical trial. This study evaluated Camzyos (mavacamten), which is a cardiac myosin inhibitor/CMI, in adolescent patients aged 12 to under 18 years suffering from symptomatic obstructive hypertrophic cardiomyopathy/oHCM. This rare genetic disease causes heart muscle thickening that obstructs blood flow, leading to sig ...